

**ANNOUNCEMENT**

The Board of Directors of Malaysian Genomics Resource Centre Berhad (hereinafter referred to as "MGRC" or "the Company") and its subsidiaries ("the Group") hereby announce the following unaudited results for the third quarter ended 30 September 2025.

**A PRESENTATION OF RESULTS**

**I CONDENSED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME**

	Individual Quarter		Year-to-Date	
	Current Period	Previous Period	Current Period	Previous Year
for the financial period ended	30.9.2025 (RM'000)	30.9.2024 (RM'000)	30.9.2025 (RM'000)	30.9.2024 (RM'000)
<b>Continuing operations</b>				
Revenue	2,484	1,401	5,629	4,478
Cost of sales	(856)	(514)	(1,873)	(2,065)
Gross profit	1,628	887	3,756	2,413
Other income	-	1	5	9
Marketing and distribution	(28)	(3)	(68)	(41)
Finance cost	(23)	(29)	(74)	(92)
Administrative expenses	(1,267)	(1,863)	(4,584)	(6,203)
<b>Profit/(Loss) before taxation</b>	<b>310</b>	<b>(1,007)</b>	<b>(965)</b>	<b>(3,914)</b>
Taxation	-	-	-	-
<b>Profit/(Loss) for the period/Total comprehensive loss for the period/year</b>	<b>310</b>	<b>(1,007)</b>	<b>(965)</b>	<b>(3,914)</b>
<b>Profit/(Loss) attributable to:</b>				
Owners of the parent	389	(928)	(729)	(3,669)
Non-controlling interests	(79)	(79)	(236)	(245)
<b>Profit/(Loss) for the period/Total comprehensive loss for the period/year</b>	<b>310</b>	<b>(1,007)</b>	<b>(965)</b>	<b>(3,914)</b>
<b>Total comprehensive income/(loss) attributable to:</b>				
Owners of the parent	389	(928)	(729)	(3,669)
Non-controlling interests	(79)	(79)	(236)	(245)
<b>Total comprehensive income/(loss) for the period/year</b>	<b>310</b>	<b>(1,007)</b>	<b>(965)</b>	<b>(3,914)</b>
<b>Earning/(Loss) per share ("EPS/LPS") attributable to the equity holders of the Company (sen)</b>				
Basic EPS/(LPS)	0.28	(0.68)	(0.53)	(2.67)
Diluted EPS/(LPS)	N/A	N/A	N/A	N/A

The unaudited condensed statement of profit and loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2024 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

Notes:-

There is no income/expense in relation to other income including investment income, gain/loss on disposal of quoted or unquoted investments or properties, gain/loss on derivatives, or exceptional items, except for as disclosed on the cashflow statement.

**A PRESENTATION OF RESULTS (cont.)**

**II CONDENSED STATEMENT OF FINANCIAL POSITION**

as at	30.9.2025 (RM'000)	31.12.2024 (RM'000)
<b>ASSETS</b>		
NON-CURRENT ASSETS		
Plant and equipment	2,474	2,946
Intangible assets	3,563	3,879
Right-of-use assets	1,159	1,443
Other investment	2,500	2,500
	<u>9,696</u>	<u>10,768</u>
CURRENT ASSETS		
Trade and other receivables	9,262	9,895
Inventories	528	937
Other current assets	228	254
Tax recoverable	304	230
Cash and bank balances	678	271
	<u>11,000</u>	<u>11,587</u>
<b>TOTAL ASSETS</b>	<b><u>20,696</u></b>	<b><u>22,355</u></b>
<b>EQUITY AND LIABILITIES</b>		
EQUITY		
Share capital	59,436	59,436
Accumulated losses	(42,009)	(41,280)
Equity attributable to the owners of the company	17,427	18,156
Non-controlling interest	(819)	(583)
<b>TOTAL EQUITY</b>	<b><u>16,608</u></b>	<b><u>17,573</u></b>
LIABILITIES		
NON-CURRENT LIABILITY		
Lease liabilities	999	1,226
	<u>999</u>	<u>1,226</u>
CURRENT LIABILITIES		
Trade and other payables	2,723	3,131
Contract liabilities	41	41
Lease liabilities	325	384
	<u>3,089</u>	<u>3,556</u>
<b>TOTAL LIABILITIES</b>	<b><u>4,088</u></b>	<b><u>4,782</u></b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b><u>20,696</u></b>	<b><u>22,355</u></b>
Net assets (RM'000)	17,427	18,156
Net assets per share attributable to equity holders of the Company (sen)	12.70	13.23

The unaudited condensed statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2024 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

**A PRESENTATION OF RESULTS (cont.)**

**III CONDENSED STATEMENT OF CHANGES IN EQUITY**

	Equity, Total	Non Distributable Share Capital	Accumulated Losses	Non- Controlling Interest
	(RM'000)	(RM'000)	(RM'000)	(RM'000)
<b>for the financial period ended 31 December 2024</b>				
Opening balance at 1 January 2024	22,087	59,436	(37,089)	(260)
Total comprehensive loss	(4,514)	-	(4,191)	(323)
<b>Closing balance at 31 December 2024</b>	<b>17,573</b>	<b>59,436</b>	<b>(41,280)</b>	<b>(583)</b>
<b>for the financial period ended 30 September 2025</b>				
Opening balance at 1 January 2025	17,573	59,436	(41,280)	(583)
Total comprehensive loss	(965)	-	(729)	(236)
<b>Closing balance at 30 September 2025</b>	<b>16,608</b>	<b>59,436</b>	<b>(42,009)</b>	<b>(819)</b>

The unaudited condensed statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2024 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

A PRESENTATION OF RESULTS (cont.)

IV CONDENSED STATEMENT OF CASH FLOWS

for the financial period ended	Year-to-Date	
	Current Year	Previous Year
	30.9.2025 (RM'000)	31.12.2024 (RM'000)
<b>Cash flows from operating activities</b>		
Loss before tax	(965)	(4,514)
Adjustments for:		
Impairment on trade and other receivables	-	121
Impairment on inventories	-	6
Amortisation of intangible assets	316	422
Depreciation of plant and equipment	517	773
Depreciation of right-of-use assets	284	379
Reversal of inventories written down	-	26
Interest expenses	74	119
Gain on disposal of plant and equipment	-	(29)
Reversal of impairment loss on trade receivables	-	(1,561)
Reversal of impairment loss on inventories	-	(29)
Operating loss before working capital changes	226	(4,287)
Decrease in receivables	659	2,738
Decrease/(Increase) in inventories	409	(320)
(Decrease)/Increase in payables	(579)	1,387
Cash generated from/(used in) operations	715	(482)
Tax paid	(74)	(151)
Interest paid	(49)	(111)
<b>Net cash generated from/(used in) operating activities</b>	<b>592</b>	<b>(744)</b>
<b>Cash flows from investing activity</b>		
Proceeds from disposal of plant and equipment	-	29
Purchase of plant and equipment	(45)	(200)
Purchase of intangible assets	-	(8)
<b>Net cash used in investing activity</b>	<b>(45)</b>	<b>(179)</b>
<b>Cash flows from financing activity</b>		
Repayment of lease liabilities	(140)	(229)
<b>Net cash used in financing activity</b>	<b>(140)</b>	<b>(229)</b>
<b>Net decrease in cash and cash equivalents</b>	<b>407</b>	<b>(1,152)</b>
<b>Cash and cash equivalents at beginning of the period</b>	<b>271</b>	<b>1,423</b>
<b>Cash and cash equivalents at end of period</b>	<b>678</b>	<b>271</b>

The unaudited condensed statement of cash flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2024 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

## UNAUDITED NOTES TO THE INTERIM FINANCIAL STATEMENTS

### B Explanatory Notes Pursuant to MFRS 134

#### i Basis of Preparation & Changes in Accounting Policies

These condensed consolidated interim financial statements have been prepared in accordance with MFRS 134 Interim Financial Reporting, and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements ("Listing Requirements") of Bursa Malaysia Securities Berhad ("Bursa Malaysia").

This report should be read in conjunction with the audited financial statements for the financial year ended 31 December 2024 and the accompanying explanatory notes. The significant accounting policies adopted in preparing these condensed consolidated interim financial statements are consistent with those of the audited financial statements for the financial year ended 31 December 2024.

Details of standards, amendments to published standards and interpretations to existing standards that are applicable to the Company with effect from 1 January 2024 or later are provided in the notes to the audited financial statements of the Group for the financial year ended 31 December 2024. The adoption of these MFRSs does not have any material impact on the Group's results and financial position.

#### ii Auditors' Report on Preceding Annual Financial Statements

The auditor opinion of audited financial statements for the financial year ended 31 December 2024 were not qualified.

#### iii Seasonal and Cyclical Factors

The operations of MGRC were not significantly affected by seasonal and cyclical factors.

#### iv Material and Unusual Items Affecting Assets, Liabilities, Equity, Net Income or Cash Flow

There were no material and unusual items affecting assets, liabilities, equity, net income or cash flows during the financial period.

#### v Material Changes in Estimates

There were no material changes in the estimates that had effect(s) on the financial period.

#### vi Debt and Equity Securities

There were no issues, repurchases and repayments of debt and equity securities for the financial period to date.

**B Explanatory Notes Pursuant to MFRS 134 (cont.)****vii Dividends Paid**

There were no dividends paid for the financial period.

**viii Segmental Information**

MFRS 8 requires identification of reporting segment on the basis of internal reports that are regularly reviewed by the entity's Executive Directors in order to allocate resources to the segment and assess its performance. The management monitors the operating results of the Group as a whole for the purpose of making decisions about resource allocation and performance assessment. Accordingly, the Group has only one reportable segment for the period under review as well as the foreseeable future. Please refer to the financial statements presented in Part A of this announcement.

**ix Valuation of Plant and Equipment**

There has been no valuation made on any of the Group's plant and equipment during the current financial period under review.

**x Subsequent Events**

There were no material events subsequent to the end of the current financial period under review that have not been reflected.

**xi Changes in the Composition of the Group**

There were no changes to the composition of the Group in the current quarter under review.

**xii Contingent Liabilities or Contingent Assets**

There was no contingent liability or contingent asset arising since the last audited statement of financial position as at 31 December 2024.

**B Explanatory Notes Pursuant to MFRS 134 (cont.)**
**xiii Capital Commitments**

The company has material capital commitments at the end of the financial period as follow:-

	<b>Current Year</b>	<b>Previous Year</b>
	<b>30.9.2025</b>	<b>30.9.2024</b>
	<b>(RM'000)</b>	<b>(RM'000)</b>
<b>Approved but not contracted for:</b>		
Purchase of others	196	141
Services	25	191
	<b>221</b>	<b>332</b>

**xiv Related Party Transactions**

Save as disclosed below, the related party transactions during the financial period to date:-

<b>for the financial period ended</b>		<b>Individual Quarter</b>		<b>Year-to-Date</b>	
		<b>Current Year</b>	<b>Previous Year</b>	<b>Current Year</b>	<b>Previous Year</b>
		<b>30.9.2025</b>	<b>30.9.2024</b>	<b>30.9.2025</b>	<b>30.9.2024</b>
<b>Related Party</b>	<b>Nature of Transaction</b>	<b>(RM'000)</b>	<b>(RM'000)</b>	<b>(RM'000)</b>	<b>(RM'000)</b>
Aquahealth Sdn Bhd	Interest	38	38	112	121
Rinani Motorsport Sdn Bhd	Rental of Motor Vehicle	-	26	17	78
360 Premier Clinic	Sales	55	-	77	-
		<b>93</b>	<b>64</b>	<b>206</b>	<b>199</b>

**xv Cash and Cash Equivalents**

	<b>Current Year</b>	<b>Previous Year</b>
<b>as at</b>	<b>30.9.2025</b>	<b>30.9.2024</b>
	<b>(RM'000)</b>	<b>(RM'000)</b>
Cash on hand and at banks	678	271

**xvi Inventories**

There was no write-down of inventories during the financial period to date.

**C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements**

These condensed consolidated interim financial statements, for the financial period ended 30 September 2025, have been prepared in accordance with Rule 9.22 and Appendix 9B of the Listing Requirements.

**i Performance of the Group**
Current Year Quarter End versus Pervious Year 3rd Quarter

For the quarter ended 30 September 2025, the Group recorded a revenue of RM2.48million, which represents an increased of RM1.08million as compared to a revenue of RM1.40million for the 3rd Quarter in the preceding year. This is mainly due to more attractive pricing package introduce by the Group and leads to higher market demand on the cell therapies and immunotherapies segment as compared to the previous year same quarter results. Besides, the clearance sales of skin care products has contributed to the increased in sales for this quarter. The Group will continue strengthening its cell therapies and expand its immunotherapy therapies, organic growth of its genetic screening business and business development activities including opening new territories and developing new products suitable for the fast-moving consumer good (FMCG) market. The Group's effort towards building its biopharmaceutical business is in support of future growth and sustainability.

For the current quarter, the Group recorded a profit before tax of RM0.31million as compared to a loss before tax of RM1.01million in the same quarter of the preceding year. The improvement was mainly attributable to higher revenue and lower administrative expenses, particularly staff costs and consultancy fees.

Current Year-to-Date versus Previous Year-to-Date

The Group recorded a revenue of RM5.63million, which represents a slightly increased of RM1.15million as compared to a revenue of RM4.48million in the previous year-to-date. The increased was mainly due to the attractive pricing package introduce by the Group and resulted to higher market demand and clearance sales of skin care products.

The Group recorded a reduced loss before tax of RM0.97 million compared to loss before tax of RM3.91 million in the corresponding period of the preceding year, primarily attributable to increased revenue and cost savings. This demonstrates the effectiveness of the cost-saving initiatives implemented by the Group.

**ii Comparison with Preceding Quarter's Results**

The comparison of this quarter's results with the preceding quarter is set out below.

	<b>Current Quarter</b>	<b>Preceding Quarter</b>	<b>Variance</b>
<b>for the financial period ended</b>	<b>30.9.2025</b>	<b>30.6.2025</b>	
	<b>(RM'000)</b>	<b>(RM'000)</b>	<b>(RM'000)</b>
Revenue	2,484	1,796	688
Profit/(Loss) before tax	310	(448)	758

A slightly higher revenue of RM2.48 million was recorded in the current period as compared to the preceding quarter's revenue of RM1.80 million, mainly due to higher demand from immunotherapy and cell therapies segments.

The Group posted a profit before tax of RM0.31 million as compared to a loss before tax of 0.45 million in the preceding quarter. This is mainly due to the higher revenue and lower administrative expenses incurred. This demonstrates the effectiveness of the cost-saving initiatives implemented by the Group.



**C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)**

**iii Prospects of the Group**

Malaysian Genomics Resource Centre Berhad (“MGRC” or “The Group”) is well-positioned to be a leading provider of genetic screening, genome analysis, and biopharmaceutical products and services in Southeast Asia. Utilising its high-throughput sequencing lab, advanced microarray facility, and state-of-the-art BSL-2 cell processing lab that is CGMP approved by MOH for production of cell and gene therapies, including immunotherapy for various types of cancer, the Group is committed to improving access to the latest in precision and personalised healthcare solutions for patients.

The Group’s strategic move to reorganise its operations had led to the formation of four distinct verticals, each focused on addressing the multi-dimensional needs of the healthcare sector which are clinical testing and biotherapeutics, specialised healthcare services, specialised manufacturing and healthcare artificial intelligence and big data.

The Group’s broad market access and diverse product portfolio have never been greater than they are today. An integral part of this requires increasing the breadth and depth of distribution networks for the Group’s products and services. To this end, MGRC seeks and engages with strategic partners across Southeast Asia, the Middle-East North Africa region and the United States. To capitalise on its growing distribution network, the Group is applying its genomics and pharmaceutical expertise to develop a portfolio of products for the fast-moving consumer goods market. This includes novel ingredients and finished products for cosmeceuticals, wound healing, and genetic-based fitness improvement programs. In Malaysia, the Group works closely with private hospitals and the Ministry of Health to improve access to its immunotherapies.

**iv Variance from Profit Forecast**

The Group did not publish any profit forecast.

**v Taxation**

There was no taxation provided for the period.

**vi Status of Corporate Proposal**

There were no significant corporate proposals for the financial period ended 30 September 2025 except for the proposed reduction of RM42,000,000 of the issued share capital of the Company pursuant to Section 116 of the Companies Act 2016 (“Act”) (“Proposed Share Capital Reduction”). Shareholders have approved the Proposed Share Capital Reduction via an Extraordinary General Meeting on 2 July 2025 and is deemed completed on 23 October 2025 upon receiving the Notice by Registrar of Companies dated 22 October 2025 that all requirements have been complied.

On 8 May 2025, M & A Securities Sdn Bhd (“M & A Securities”) on behalf of the Board of Directors (“Board”) of MGRC announced that the Company proposed private placement of up to 13,721,000 new ordinary shares in MGRC (“MGRC Share(s)” or “Share(s)”), representing not more than 10.0% of the total number of issued ordinary shares in MGRC, to independent third-party investor(s) to be identified and at an issue price to be determined at a later date (“Proposed Private Placement”) but has not been completed as at date of this announcement.

**C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)**
**vii Material Litigations**

As at the date of this announcement, there is no material litigation against the Group or taken by the Group.

**viii Dividends**

There were no dividends paid for the financial period.

**ix Trade receivables**

The ageing analysis of the Group's trade receivables is as follows:-

	<b>30.9.2025 (RM'000)</b>
Not past due	218
Past due	
- 1 to 30 days	105
- 31 to 60 days	52
- 61 to 90 days	9
- more than 90 days	9,922
	10,088
Gross	10,306
Impaired	(6,275)
Net	4,031

Receivables that are past due but not impaired

The Group believes that no further impairment allowance is necessary in respect of these trade receivables. They are substantially companies with good collection track record and no recent history of default.

**x EPS/(LPS)**

- a) **Basic EPS/(LPS)** Computed by dividing the loss after tax, attributable to owners of the parent for the financial period by the weighted average of the number of ordinary shares in issue during the period.

<b>Basic EPS/(LPS)</b>	<b>Individual Quarter</b>		<b>Year-to-Date</b>	
	<b>Current Year</b>	<b>Previous Year</b>	<b>Current Year</b>	<b>Previous Year</b>
<b>for the financial period ended</b>	<b>30.9.2025</b>	<b>30.9.2024</b>	<b>30.9.2025</b>	<b>30.9.2024</b>
Profit/(Loss) after tax, attributable to owners of the parent (RM'000)	389	(928)	(729)	(3,669)
Weighted average number of ordinary shares in issue ('000)	137,210	137,210	137,210	137,210
<b>Basic EPS/(LPS) (sen)</b>	<b>0.28</b>	<b>(0.68)</b>	<b>(0.53)</b>	<b>(2.67)</b>

- b) **Diluted EPS/(LPS)**. The Company does not have any convertible shares or convertible financial instruments for the current financial quarter and financial period to date.

**C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)**
**xi Status of Utilisation of Proceeds**

a)	Proposed utilisation of proceeds from private placement	Proposed utilisation timeframe	Proposed Utilisation (RM'000)	Variation (RM'000)	Actual Utilisation (RM'000)	Balance of Amount Allocated (RM'000)
	Future viable investment	Within 24 months from completion	3,620	(60)	(2,560)	1,000
	Working capital*	Within 12 months from listing	413	-	(413)	-
	Estimated expenses	Upon completion	-	60	(60)	-
			<u>4,033</u>	<u>-</u>	<u>(3,033)</u>	<u>1,000</u>

\* In the event the Company is unable to identify any suitable and viable opportunities within the timeframe stipulated (or any extended timeframe, if applicable), the proceeds allocated for future viable investments shall be utilised as working capital of the Group.

**xii Authorisation for Issue**

The interim financial statements were approved and authorised for issue by the Board of Directors of MGRC on 24 November 2025.